Search clinical trials for: ERBITUX

Total 435 results

Bristol-Myers Squibb

Terminated

Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors

Head and Neck Cancer | Neoplasm Metastasis | Colorectal Cancer

United States, Canada
Merck KGaA, Darmstadt, Germany

Completed

A Korean Post-marketing Surveillance Study on Erbitux® in Patients With Metastatic Colorectal Cancer Refractory to Irinotecan-containing Treatment

Colorectal Neoplasms

Korea, Republic of
TyrNovo Ltd.

Active, not recruiting

A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer

Head and Neck Cancer | Squamous Cell Carcinoma of Head and Neck | Metastatic Solid Tumor | Colorectal Adenocarcinoma | Solid Tumor, Adult | Recurrent Solid Tumor

United States, Israel
Groupe Oncologie Radiotherapie Tete et Cou

Completed

Trial of OTD70DERM® in Radio-dermatitis Induced by Radiotherapy-Erbitux® (GORTEC 2009-01)

Head and Neck Carcinoma

France
Heinrich-Heine University, Duesseldorf

Completed

Adjuvant Cetuximab and Chemoradiation in Head and Neck Cancer (ACCRA-HN)

Head and Neck Cancer

Germany
Eli Lilly and Company
Bristol-Myers Squibb

Completed

Phase II Study in Patients With Recurrent Non-Small-Cell Lung Cancer

Non-Small-Cell Lung Cancer

United States
Eli Lilly and Company

Completed

Study of IMC-A12, Alone or in Combination With Cetuximab, in Participants With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck

Head and Neck Cancer

United States
Groupe Oncologie Radiotherapie Tete et Cou

Completed

Reirradiation and Erbitux in the HNSCC

Head and Neck Cancer Squamous Cell

France
Rambam Health Care Campus
Merck KGaA, Darmstadt, Germany

Completed

Does Acne Rash During Adolescence Predict Skin Reaction to Cetuximab

Colorectal Cancer Metastatic

Israel
Merck KGaA, Darmstadt, Germany
Merck, S.L., Spain

Completed

Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable FcγRIIa (CD32) Genotype (MUTEX)

Colorectal Neoplasms

Spain
Eli Lilly and Company

Completed

Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors

Advanced Cancer

Puerto Rico, United States
Merck KGaA, Darmstadt, Germany

Completed

Prospective, Post Marketing Surveillance Study On Erbitux® (Cetuximab) in Patients With Locally Advanced or Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck in Korea

Head and Neck Cancer

Korea, Republic of
Karolinska University Hospital

Unknown

Randomised Phase II, Cetuximab in Combination With 5FU and Cisplatin or Carboplatin Versus Cetuximab in Combination With Paclitaxel and Carboplatin for Treatment of Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck (CETMET)

Squamous Cell Carcinoma of the Head and Neck

Denmark, Sweden
Eli Lilly and Company
Bristol-Myers Squibb

Completed

A Study of Cetuximab in Patients Who Have Stage IV Colorectal Cancer

Colorectal Neoplasms

United States
Memorial Sloan Kettering Cancer Center
Eli Lilly and Company; National Comprehensive Cancer Network

Completed

Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Squamous Cell Cancer | Head and Neck

United States
Sorlandet Hospital HF
Merck KGaA, Darmstadt, Germany; Frontier Science & Technology Research Foundation...

Completed

Novel Treatment Option for Neuropathic Pain (NoTOPain)

Neuralgia | Complex Regional Pain Syndromes

Norway
Centre Hospitalier of Chartres
Hospital of Chartres- France

Completed

Study of Cetuximab in Squamous Cell Carcinoma of the Skin Expressing EGFR (CTXSCC)

Skin Diseases | Carcinoma, Squamous Cell

France
Merck KGaA, Darmstadt, Germany
Merck Ltd., India

Terminated

An Observational Study to Evaluate the Safety and Efficacy of Cetuximab in Combination With Platinum-based Chemotherapy in the First-line Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

Carcinoma, Squamous Cell

India
Dana-Farber Cancer Institute
Bristol-Myers Squibb; Massachusetts General Hospital; Beth Israel Deaconess Medical...

Completed

Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric Cancer

Neoplasm Metastasis | Gastric Cancer | Esophageal Cancer

United States
Merck KGaA, Darmstadt, Germany

Withdrawn

A Post-marketing Surveillance Study on Erbitux in Combination With Platinum-based Chemotherapy in Metastatic/Recurrent Squamous Cell Cancer of the Head and Neck

Neoplasms, Squamous Cell
Merck KGaA, Darmstadt, Germany
Merck Ltd.

Terminated

An Observational Study of Erbitux® in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing Treatment

Colorectal Neoplasm

Korea, Republic of
ARCAGY/ GINECO GROUP

Terminated

Phase II Study , Association of Cisplatine Topotecan and Cetuximab in Patients Whith Late or in Progress Epithelial Cancer of the Cervix (ERBUS)

Cervix Cancer

France
Eli Lilly and Company
Bristol-Myers Squibb

Terminated

A Study in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma

Ovarian Cancer

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

Esophageal Cancer

United States
University of Pittsburgh
Bristol-Myers Squibb

Completed

Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLC

Non Small Cell Lung Cancer (NSCLC)

United States
Heidelberg University
Merck KGaA, Darmstadt, Germany; University Hospital Heidelberg; Dept. of Radiation...

Unknown

Adenoid Cystic Carcinoma, Erbitux, and Particle Therapy (ACCEPT)

Adenoid Cystic Carcinoma

Germany
M.D. Anderson Cancer Center

Not yet recruiting

Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer

Advanced Colorectal Cancer

United States
Merck KGaA, Darmstadt, Germany
Merck Ltd., India

Terminated

A Post Marketing Surveillance Study to Assess the Safety and Efficacy of Cetuximab Plus Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck (PMS LAD SCCHN)

Unresectable Locally Advanced Squamous Cell Carcinoma of Head and Neck | LA SCCHN

India
Lecia V. Sequist
Bristol-Myers Squibb; Dana-Farber Cancer Institute; Beth Israel Deaconess Medical... and other collaborators

Terminated

Cetuximab as Therapy for Recurrent Non-Small Cell Lung Cancer Patients Who Have Received Prior Therapy

Non-small Cell Lung Cancer

United States
Sun Yat-sen University
Fudan University; Cancer Institute and Hospital, Chinese Academy of Medical... and other collaborators

Completed

Study of Cetuximab in Nasopharyngeal Carcinoma (NPC) With Chemoradiotherapy (ENCORE)

Nasopharyngeal Carcinoma

China
University of Maryland, Baltimore
Bristol-Myers Squibb

Completed

Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck (GCC 0442)

Cancer of Head and Neck

United States
University of Wisconsin, Madison
National Institute of Dental and Craniofacial Research (NIDCR); American Cancer...

Completed

Cetuximab in Head and Neck Cancer Patients

Head and Neck Cancer | Squamous Cell Carcinoma

United States
University of Zurich

Completed

A Phase II Study In Patients With Advanced Head And Neck Cancer Of Standard Chemoradiation And Add-On Cetuximab

Laryngeal Cancer | Hypopharyngeal Cancer | Oropharyngeal Cancer

Switzerland
University Hospital, Ghent
Merck Sharp & Dohme LLC

Completed

A Study of Cetuximab Combined With Cisplatin or Carboplatin/Pemetrexed as First Line Treatment in Patients With Malignant Pleural Mesothelioma. (MesoMab)

Cancer

Belgium, Netherlands
Eli Lilly and Company

Completed

A Trial of Erbitux for Recurrent and Metastatic Mucinous Gastrointestinal Adenocarcinoma Involving the Peritoneal Surfaces

Mucinous Gastrointestinal Adenocarcinoma

United States
Eli Lilly and Company

Completed

Study of Erbitux (Cetuximab) in Patients With Metastatic Colorectal Carcinoma

Colorectal Neoplasms | Metastases, Neoplasm

United States
King Faisal Specialist Hospital & Research Center

Completed

A Trial of Pre-Operative Chemoradiotherapy Using Capecitabine, Radiation & Cetuximab, in Rectal Cancer

Colon Rectal Cancer Duke Stage Stageval

Saudi Arabia
Northwell Health

Terminated

Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck

Carcinoma, Squamous Cell | Carcinoma, Squamous Cell of Head and Neck

United States
Ruijin Hospital
Henan Cancer Hospital; Second Affiliated Hospital, School of Medicine, Zhejiang... and other collaborators

Unknown

Cetuximab Monotherapy Maintenance Treatment in mCRC

Colorectal Cancer
Eli Lilly and Company

Completed

An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer

Metastatic Colorectal Cancer

Spain, United States, Canada
Melanoma and Skin Cancer Trials Limited

Not yet recruiting

Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma (NEOPECS)

Locally Advanced Cutaneous Squamous Cell Carcinoma
Eli Lilly and Company
Bristol-Myers Squibb

Completed

Carboplatin Plus Cetuximab for Treatment of Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

United States
West China Hospital

Recruiting

Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer

BRAF V600E-mutated /MSS Metastatic Colorectal Cancer | Vemurafenib (BRAFi) Plus Cetuximab (EGFRi) Combined With PD-1 Monoclonal Antibody

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer

Colorectal Cancer

China
Pierre Fabre Pharma GmbH
iOMEDICO AG; Pierre Fabre Pharma Austria; Pierre Fabre Pharma AG

Recruiting

BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation of Next Generation CRC Treatment (BERING-CRC)

Metastatic Colorectal Carcinoma

Austria, Germany
Ruijin Hospital
Xiangya Hospital of Central South University; Chinese PLA General Hospital; West... and other collaborators

Not yet recruiting

Cetuximab Maintenance Treatment Versus Continuation After Induction Therapy in mCRC

Colorectal Cancer
University of Cincinnati

Completed

Post-operative Radiation With Cetuximab for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck

Head and Neck Cancer

United States
David A. Clump, MD, PhD

Completed

Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck

Squamous Cell Carcinoma of the Head and Neck

United States
Intergroupe Francophone de Cancerologie Thoracique

Completed

Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC)

Stage III Non-small Cell Lung Cancer

France
National Health Research Institutes, Taiwan
Kaohsiung Medical University Chung-Ho Memorial Hospital; Taipei Veterans General... and other collaborators

Unknown

The Emergence of RAS Mutations in Metastatic Colorectal Cancer Patients Receiving Cetuximab Treatment

Colorectal Cancer | Drug Resistance | Mass Spectrometry | RAS-RAF Pathway Deregulation

Taiwan

Search clinical trials for: ERBITUX

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Trinidad & Tobago

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations